Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.
Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperform and raises the price target from $76 to $86.